INTELLIGENT BIO SOLUTIONS INC. — fact timeline

INTELLIGENT BIO SOLUTIONS INC. reported the fiscal third quarter and nine months ended March 31, 2026 results: revenue Total revenue of $1.06 million, up 46% year-over-year.

“except as shall be expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales Nine-month revenue reaches $3.07”

INTELLIGENT BIO SOLUTIONS INC. issued 2,298,850 shares of warrant to two healthcare focused institutional investors for $4.10 per share.

“Each Series K-1 Warrant and Series K-2 Warrant is exercisable into one share of Common Stock at a price per share of $4.10 (as adjusted from time to time in accordance with the terms thereof).”

INTELLIGENT BIO SOLUTIONS INC. issued 2,298,850 shares of common stock to two healthcare focused institutional investors for $4.35 per share.

“The combined purchase price of one share of Common Stock (or one Pre-Funded Warrant) and accompanying Series K-1 Warrant and Series K-2 Warrant was $4.35. The Offering closed on January 2, 2026. At the closing of the Offering, 105,000 Shares were issued and 2,193,850 Pre-Funded Warrants were issued.”

INTELLIGENT BIO SOLUTIONS INC. entered into Securities Purchase Agreement with two healthcare focused institutional investors valued at approximately $10.0 million (effective 2025-12-31).

“On December 31, 2025, Intelligent Bio Solutions Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with two healthcare focused institutional investors for the sale by the Company of (i) 2,298,850 shares (the “Shares”) of the Company’s common stock (or Series L Pre-funded warrants in lieu thereof (the “Pre-Funded Warrants”)), par value $0.01 per share (the “Common Stock”), (ii) Series K-1 warrants to purchase up to an aggregate of 2,298,850 shares of Common Stock (the “Series K-1 Warrants”), and (iii) Series K-2 warrants to purchase up to an aggregate of 2,298,850 shares of Common Stock (the “Series K-2 Warrants” and, collectively with the Series K-1 Warrants and Pre-Funded Warrants, the “Warrants”), in a private placement offering (the “Offering”).”

INTELLIGENT BIO SOLUTIONS INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 15, 2025, Intelligent Bio Solutions Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that because the closing bid price for the Company’s common stock was below $1.00 per share for the last 30 consecutive business days, the Company did not meet the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter does not result in the immediate delisting of the Company’s common”

INTELLIGENT BIO SOLUTIONS INC. issued common stock.

“it will effect a 1-for-10 reverse split of its common stock, that will become effective at 11:59 pm (Eastern Time) on December 15, 2025”

INTELLIGENT BIO SOLUTIONS INC.: Approved amendment to Certificate of Incorporation to effect a 1-for-10 reverse stock split (effective 2025-12-15).

“At the annual meeting of stockholders of Intelligent Bio Solutions Inc. (the “Company”) held on October 16, 2025, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”) to effect a reverse stock split at a ratio of not less than 1-for-2 and not more than 1-for-10 at any time within 12 months following the date of such stockholder approval, with the exact ratio to be set within this range by the Company’s Board of Directors (the “Board”) at its sole discretion without further approval or authorization of the Company’s stockholders.”

Nicola Fraser was appointed as Director at INTELLIGENT BIO SOLUTIONS INC..

“On June 7, 2024, upon recommendation of the Nominating and Corporate Governance Committee, the Board appointed Nicola Fraser to the Board to fill the vacancy created by Mr. Tower’s resignation.”

Christopher Towers resigned as Director at INTELLIGENT BIO SOLUTIONS INC..

“On June 6, 2024, Christopher Towers resigned from the Board of Directors (the “Board”) of Intelligent Bio Solutions Inc. (the “Company”), effective June 7, 2024.”

INTELLIGENT BIO SOLUTIONS INC. reported nine months ended March 31, 2024 results: revenue $2.38 million, net income $7.37 million.

“Total revenue for the nine months ended March 2024 was $2.38 million, an increase of 193% compared to the same period the year prior.”

INTELLIGENT BIO SOLUTIONS INC. reported fiscal third quarter ended March 31, 2024 results: revenue $0.82 million, net income $2.98 million.

“Total revenues for the fiscal third quarter were $0.82 million, an increase of 80% compared to the same period the year prior.”

INTELLIGENT BIO SOLUTIONS INC. reported the fiscal third quarter and nine months ended March 31, 2024 results: revenue $0.82 million.

“today announced preliminary unaudited revenue results for the fiscal third quarter and nine months ended March 31, 2024. The Company expects approximate unaudited revenue of $0.82 million for the three months ended March 31, 2024, representing an increase of 80% compared to the same period the prior year, and approximate unaudited revenue of $2.38 million for the”

INTELLIGENT BIO SOLUTIONS INC. entered into Securities Purchase Agreement with several institutional and accredited investors (effective 2024-03-08).

“On March 8, 2024, Intelligent Bio Solutions Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with several institutional and accredited investors”

INTELLIGENT BIO SOLUTIONS INC. entered into Consulting Agreement with C2C Advisors Inc. valued at $25,000 per month (effective 2024-02-29).

“On February 29, 2024, Intelligent Bio Solutions Inc. (the “Company”) entered into a Consulting Agreement (the “C2C Agreement”) with C2C Advisors Inc. (“C2C”) pursuant to which C2C will provide certain advisory and investor relations services to the Company.”

INTELLIGENT BIO SOLUTIONS INC. reported financial results for fiscal second quarter and six months ended December 31, 2023.

“On February 9, 2024, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”) announcing financial results for the three months ended December 31, 2023.”

INTELLIGENT BIO SOLUTIONS INC. entered into Agreements with certain accredited and institutional holders valued at approximately $1.77 million (effective 2024-02-04).

“On February 4, 2024, Intelligent Bio Solutions Inc. (the “Company”) entered into warrant inducement agreements (the “Agreements”) with certain accredited and institutional holders (collectively, the “Holders”) of the Company’s outstanding Series E Warrants issued on October 4, 2023”

INTELLIGENT BIO SOLUTIONS INC. reported fiscal second quarter and six months ended December 31, 2023 results: revenue $0.76 million for the second fiscal quarter ended December 31, 2023.

“The Company expects approximate unaudited revenue of $1.56 million for the six months ended December 31, 2023, representing a significant increase of 337% compared to the same period the prior year, and approximate unaudited revenue of $0.76 million for the second fiscal quarter ended December 31, 2023, representing an increase of 114% compared to the same period the prior year.”

INTELLIGENT BIO SOLUTIONS INC.: Amendment to Amended and Restated Certificate of Incorporation to effect a 1-for-12 reverse stock split (effective 2024-01-26).

“On January 26, 2024, the Amendment was filed with the Secretary of State of the State of Delaware and the Reverse Stock Split became effective in accordance with the terms of the Amendment at 5:00 p.m. Eastern Time on January 26, 2024 (the “Effective Time”).”

INTELLIGENT BIO SOLUTIONS INC. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

“January 2, 2024, to submit a plan to regain compliance with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1). On December 15, 2023, the Company submitted a compliance plan to Nasdaq that included a pro forma balance sheet as of October 31, 2023 (the “Balance Sheet”). The Balance Sheet showed that the Company’s stockholders’ equity as of October 31, 2023, was $4,240,629, which was primarily the result of the of a public offering of the Company’s securities that closed on October 4, 2023. The Balance Sheet was also attached to a Current Report on Form 8-K filed b”

INTELLIGENT BIO SOLUTIONS INC. shareholders approved The approval of the amendment of the Company’s 2019 Long Term Incentive Plan (the “2019 Plan”) to increase the number of shares of common stock authorized for issuance under the 2019 Plan by 1,475,000 shares and to increase the limit on the maximum number of shares underlying awards to any non-emplo at the 2023-12-13 meeting.

“Proposal 3. The approval of the amendment of the Company’s 2019 Long Term Incentive Plan (the “2019 Plan”) to increase the number of shares of common stock authorized for issuance under the 2019 Plan by 1,475,000 shares and to increase the limit on the maximum number of shares underlying awards to any non-employee director in any year to 15,000 shares in any year (the “2019 Plan Amendment Proposal”). Votes For Votes Against Abstain Broker Non-Votes 1,515,129 235,051 3,728 1,298,111”

INTELLIGENT BIO SOLUTIONS INC. shareholders approved The approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio not less than 1-for-2 and not greater than 1-for-12, with the exact ratio to be set within that range at the discretion of our Board of Directors without further at the 2023-12-13 meeting.

“Proposal 2. The approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio not less than 1-for-2 and not greater than 1-for-12, with the exact ratio to be set within that range at the discretion of our Board of Directors without further approval or authorization of our stockholders (the “Reverse Stock Split Proposal”). Votes For Votes Against Abstain Broker Non-Votes 2,456,199 590,016 5,804 0”

INTELLIGENT BIO SOLUTIONS INC. shareholders approved Election of five directors, each to serve until the next annual meeting of stockholders, or until each successor is duly elected and qualified. at the 2023-12-13 meeting.

“Proposal 1. The election of five directors, each to serve until the next annual meeting of stockholders, or until each successor is duly elected and qualified. Nominee Votes For Votes Withheld Broker Non-Votes Stephen Boyages 1,549,332 204,576 1,298,111 Lawrence Fisher 1,547,779 206,129 1,298,111 Jonathan Hurd 1,547,504 206,404 1,298,111 Jason Isenberg 1,547,783 206,125 1,298,111 Christopher Towers 1,547,443 206,465 1,298,111”

INTELLIGENT BIO SOLUTIONS INC. shareholders approved Authorization of an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 1 at the 2023-11-17 meeting.

“Proposal 3. Authorization of an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 1. VOTES FOR VOTES AGAINST ABSTENTIONS BROKER NON-VOTES 794,254 284,744 1,592 42,853”

INTELLIGENT BIO SOLUTIONS INC. shareholders approved Ratification of the appointment of UHY LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2024 at the 2023-11-17 meeting.

“Proposal 2. R atification of the appointment of UHY LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2024. VOTES FOR VOTES AGAINST ABSTENTIONS BROKER NON-VOTES 957,940 157,789 7,714 -0-”

INTELLIGENT BIO SOLUTIONS INC. shareholders approved Approval, for purposes of complying with Nasdaq Listing Rules 5635(c) and (d), of the issuance of up to 15,921,888 shares of common stock (or 16,727,272 shares if the full overallotment option is exercised) upon the exercise of the Warrants issued by the Company in a public offering that closed on O at the 2023-11-17 meeting.

“Proposal 1. A pproval, for purposes of complying with Nasdaq Listing Rules 5635(c) and (d), of the issuance of up to 15,921,888 shares of common stock (or 16,727,272 shares if the full overallotment option is exercised) upon the exercise of the Warrants issued by the Company in a public offering that closed on October 4, 2023 (“Proposal 1”). VOTES FOR VOTES AGAINST ABSTENTIONS BROKER NON-VOTES 509,897 116,224 2,040 495,282”

INTELLIGENT BIO SOLUTIONS INC. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000. In the Company’s Form 10-Q, the Company reported stockholders’ equity of $1,236,558, which is below the minimum stockholders’ equity required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1). As indicated in Nasdaq’s letter, as of November 15,”

INTELLIGENT BIO SOLUTIONS INC. reported fiscal first quarter ended September 30, 2023 results: revenue combined revenue and government support income increased by 191% to $0.91 million, net income Net loss attributable to INBS for the first fiscal quarter ended September 30, 2023 was $2.4 million.

“The Company’s combined revenue and government support income increased by 191% to $0.91 million for the first fiscal quarter ended September 30, 2023, including revenue from sales of goods of $0.8 million, compared to $0 in the first fiscal quarter ended September 30, 2022.”

David Jenkins retired as Director at INTELLIGENT BIO SOLUTIONS INC..

“On November 6, 2023, David Jenkins informed the Board of Directors (the “Board”) of Intelligent Bio Solutions Inc. (the “Company”) that he has decided to retire from service on the Board and will not stand for reelection to the Board at the Company’s annual meeting of stockholders for the fiscal year ended June 30, 2023 (the “2023 Annual Meeting”).”

INTELLIGENT BIO SOLUTIONS INC.: Filed Certificate of Designation for Series E Convertible Preferred Stock, designating 5,728,723 shares of Series E Preferred Stock, with no voting rights, convertible into common stock, and no dividends unless declared by the board (effective 2023-10-03).

“In connection with the Public Offering, the Company filed the Certificate of Designation of Preferences, Rights and Limitations of the Series E Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware on October 3, 2023.”

INTELLIGENT BIO SOLUTIONS INC. entered into Underwriting Agreement with Ladenburg Thalmann & Co. Inc. (effective 2023-10-02).

“On October 2, 2023, Intelligent Bio Solutions Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Ladenburg Thalmann & Co. Inc., as representative (the “Representative”) of the underwriters named in Schedule I thereto (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell, in a registered public offering by the Company (the “Public Offering”): (a) 1,544,004 Class A Units”

INTELLIGENT BIO SOLUTIONS INC. reported fiscal year ended June 30, 2023 results: revenue $1.99 million, net income $10.6 million loss.

“The Company’s combined revenue and government support income increased by 355% to $1.99 million for the fiscal year ended June 30, 2023, including revenue from sales of goods of $1.26 million, compared to fiscal year 2022.”

INTELLIGENT BIO SOLUTIONS INC.: Elimination of Series B and Series D Convertible Preferred Stock designations, shares reverted to undesignated preferred stock (effective 2023-07-25).

“On July 25, 2023, Intelligent Bio Solutions Inc. (the “Company”) filed a Certificate of Elimination of Series B Convertible Preferred Stock (the “Series B Certificate of Elimination”) with the Secretary of State of the State of Delaware (the “Delaware SOS”) effecting the elimination of its Series B Convertible Preferred Stock.”

INTELLIGENT BIO SOLUTIONS INC. engaged UHY LLP as its auditor.

“on June 29, 2023, the Audit Committee approved the appointment of UHY LLP (“UHY”) as the Company’s independent registered public accounting firm for the year ending June 30, 2023.”

BDO Audit Pty Ltd. resigned as auditor of INTELLIGENT BIO SOLUTIONS INC..

“on June 29, 2023, BDO Audit Pty Ltd. (“BDO”) resigned as the Company’s independent registered public accounting firm effective June 29, 2023.”

George Margelis resigned as Director at INTELLIGENT BIO SOLUTIONS INC..

“On June 9, 2023, Dr. George Margelis , a member of the Board of Directors (the “Board”) of Intelligent Bio Solutions Inc. (the Company”), and a member of the Audit Committee of the Board (the “Audit Committee”), resigned as a member of the Board effective as of such date.”

INTELLIGENT BIO SOLUTIONS INC. reported fiscal third quarter ended March 31, 2023 results: revenue $457,058, net income $6.34 million, EPS $5.72 per share.

“The Company’s combined revenue and government support income increased by 199% or $382,238 to $574,738 for the three months ending March 31, 2023, including revenue of $457,058, compared to the same period in 2022. The year-over-year revenue increase reflects the acquisition of Intelligent Fingerprinting Ltd. during the fiscal 2023 second quarter and the”

INTELLIGENT BIO SOLUTIONS INC. shareholders approved To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies.

“FOR AGAINST ABSTAIN 583,313 25,538 613”

INTELLIGENT BIO SOLUTIONS INC. shareholders approved To approve an increase in the number of shares of Common Stock authorized for issuance under the 2019 Plan by 50,000 shares.

“FOR AGAINST ABSTAIN 584,036 25,164 264”

INTELLIGENT BIO SOLUTIONS INC. shareholders approved To approve the full conversion of Series D Convertible Preferred Stock and the issuance of shares of Common Stock in connection with such conversion.

“FOR AGAINST ABSTAIN 585,379 23,657 428”

INTELLIGENT BIO SOLUTIONS INC. shareholders approved To approve the full conversion of Series C Convertible Preferred Stock and the issuance of shares of Common Stock in connection with such conversion.

“FOR AGAINST ABSTAIN 530,145 7,392 71,927”

INTELLIGENT BIO SOLUTIONS INC. entered into Underwriting Agreement with Ladenburg Thalmann & Co. Inc., as representative of the several underwriters valued at approximately $2.55 million (effective 2023-03-08).

“On March 8, 2023, Intelligent Bio Solutions Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Ladenburg Thalmann & Co. Inc., as representatives (the “Representative”) of the several underwriters named in Schedule I thereto (collectively, the “Underwriters”), relating to an underwritten public offering of 569,560 shares”

INTELLIGENT BIO SOLUTIONS INC. reported fiscal second quarter ended December 31, 2022 results: net income $0.42 million or $0.46 per share, EPS $0.46 per share.

“For the quarter that ended December 31, 2022, the Company had a net loss of $0.42 million or $0.46 per share”

INTELLIGENT BIO SOLUTIONS INC.: Amended articles to effect a reverse stock split at a ratio set by the board, resulting in a 1-for-20 reverse split effective February 9, 2023 (effective 2023-02-09).

“At the Annual Meeting the stockholders of the Company approved an amendment to the Company’s Amended And Restated Articles Of Incorporation (the “Amendment”) to effect the reverse stock split at a ratio of not less than 1-for-2 and not more than 1-for-35 at any time within 12 months following the date of stockholder approval, with the exact ratio to be set within this range by the Company’s Board of Directors (the “Board”) at its sole discretion without further approval or authorization of our stockholders.”

INTELLIGENT BIO SOLUTIONS INC. shareholders approved Authorization of adjournment of Annual Meeting if necessary to solicit additional proxies if not sufficient votes in favor of Proposal 4.

“Proposal 6. The authorization of the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 4.”

INTELLIGENT BIO SOLUTIONS INC. shareholders approved Authorization of adjournment of Annual Meeting if necessary to solicit additional proxies if not sufficient votes in favor of Proposal 3.

“Proposal 5. The authorization of the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 3.”

INTELLIGENT BIO SOLUTIONS INC. shareholders approved Approval of increase in shares authorized for issuance under 2019 Long Term Incentive Plan by 1,000,000 shares.

“Proposal 4. The approval of an increase in the number of shares of common stock authorized for issuance under the Company’s 2019 Long Term Incentive Plan by 1,000,000 shares.”

INTELLIGENT BIO SOLUTIONS INC. shareholders approved Approval of amendment to Certificate of Incorporation to effect reverse stock split at ratio not less than 1-for-2 and not greater than 1-for-35.

“Proposal 3. The approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio not less than 1-for-2 and not greater than 1-for-35, with the exact ratio to be set within that range at the discretion of our Board of Directors without further approval or authorization of our stockholders.”

INTELLIGENT BIO SOLUTIONS INC. shareholders approved Ratification of appointment of BDO Audit Pty Ltd as independent registered public accounting firm for year ending June 30, 2023 at the 2023-06-30 meeting.

“Proposal 2. The ratification of the appointment of BDO Audit Pty Ltd as the Company’s independent registered public accounting firm for the year ending June 30, 2023.”

INTELLIGENT BIO SOLUTIONS INC. shareholders approved Election of seven directors.

“Proposal 1. The election of seven directors, each to serve until the next annual meeting of shareholders, or until each successor is duly elected and qualified.”

INTELLIGENT BIO SOLUTIONS INC. entered into Engagement Letter with Winx Capital Pty Ltd. (effective 2022-12-16).

“On December 16, 2022, the Company entered into Engagement Letter (the “Engagement Letter”) with Winx Capital Pty Ltd. ( CAR for AFSL (Australian Financial Services License) #330757) (“Winx Capital”) pursuant to which Winx Capital agreed to serve as a consultant acting as placement agent on a best efforts basis in connection with the private placement of the Units in the Transaction.”